Development pipeline

Indatuximab Ravtansine (BT-062)

Indatuximab Ravtansine (BT-062) is an immune conjugate, consisting of a monoclonal antibody to which a highly effective cytotoxic maytansien derivative (DM4) is coupled. The immune conjugate technology, developed by ImmunoGen, Inc, is used for toxin conjugation. The antibody is directed against the CD138 receptor, which is over-expressed on multiple myeloma cells and on other cells of various types of cancer: solid tumors.

After the conjugate is absorbed into the target cell, DM4 is released and exerts its cytotoxic activity so that the tumor cell is killed. This combination of high effectiveness and specificity with low systemic toxicity distinguishes BT-062 from most therapies currently used in oncology.

Press releases

Biotest reaches 2017 profit guidance

22.03.2018,

PRESS RELEASEBiotest reaches 2017 profit guidance- Adjusted EBIT stable- Five new plasmapheresis centres opened in Europe- Biotest Next Level: building acceptance obtained and successful "Good Manufac ... [More]

First patient with aquired fibrinogen deficiency treate...

15.03.2018,

PRESS RELEASEFirst patient with aquired fibrinogen deficiency treated in clinical phase III study of Biotest AG - Important milestone reached in the clinical development programme of fibrinogen concen ... [More]

Biotest supports a large international registry study t...

13.03.2018,

PRESS RELEASE Biotest supports a large international registry study to record data on use of Pentaglobin(R) in patients with severe bacterial infections- High medical need due to high mortality a ... [More]

Biotest reaches FY 2017 EBIT guidance

27.02.2018,

Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Biotest reaches FY 2017 EBIT guidanceDreieich, 27 February 2018. According to preliminary and unaudited figures ... [More]

Tiancheng intends to enter into a domination and profit...

08.02.2018,

Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Tiancheng intends to enter into a domination and profit and loss transfer agreement with Biotest AGDreieich, 8 ... [More]

Release according to Article 40, Section 1 of the WpHG ...

02.02.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Release according to Article 40, Section 1 of the WpHG ...

01.02.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Creat takeover of Biotest closed

31.01.2018,

/PRESS RELEASE Creat takeover of Biotest closed- Transfer of tendered shares completed- Majority shareholding (approx. 90% of Biotest AG's ordinary shares and voting share capital) of Creat in Bi ... [More]

Biotest AG opens second plasma collection centre in Cze...

24.01.2018,

/PRESS RELEASEBiotest AG opens second plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 24 January 2018. Biotest received an ... [More]

All conditions met for Creat takeover of Biotest

19.01.2018,

/Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)All conditions met for Creat takeover of BiotestDreieich, 19. January 2018. Biotest AG disclosed today that fo ... [More]

Release according to Article 40, Section 1 of the WpHG ...

11.01.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Trimodulin: concept for phase III study successfully co...

20.12.2017,

/PRESS RELEASETrimodulin: concept for phase III study successfully coordinated with the authorities- Clinical concept of the Phase III study is supported by the regulatory authorities- Optimized produ ... [More]

Preliminary announcement of the publication of financia...

06.12.2017,

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 22, 2018 Date of disclosure / English: March ... [More]

Preliminary announcement of the publication of quarterl...

06.12.2017,

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Quarterly financial report within the 1st half-year (Q1) Date of disclosure / German: May 15, 2018 Date ... [More]

Biotest supports a randomized multicenter controlled tr...

05.12.2017,

/PRESS RELEASEBiotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin(R) lead by Aachen University- Trial investigates personalized treatment approach ... [More]

Biotest generates revenues of EUR 377.8 million in the ...

14.11.2017,

PRESS RELEASEBiotest generates revenues of EUR 377.8 million in the first nine months 2017- Successful regulatory inspection and approval of Biotest Next Level in August- Paul-Ehrlich Institute approv ... [More]

Tender Offer by Tiancheng (Germany) Pharmaceutical Hold...

07.11.2017,

/Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Tender Offer by Tiancheng (Germany) Pharmaceutical Holdings AG / Tiancheng withdrawal of application of transa ... [More]

Biotest AG opens eighth plasma collection centre in Hun...

06.11.2017,

/PRESS RELEASEBiotest AG opens eighth plasma collection centre in Hungary- 17 plasma collection centres in Europe and- 22 in the USA to ensure long-term plasma supplyDreieich, 6 November 2017. Biotest ... [More]

Correction of a release from 24.10.2017, 10:28 CET/CEST...

26.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Release according to Article 26, Section 1 of the WpHG ...

24.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights X Acquisition/d ... [More]

Conference dates

03.12.2016 – 06.12.2016 | San Diego

Publications

preview

ASH 2014 American Society of Hematology (06.12.2014 – 09.12.2014, San Francisco)
PDF, 398.98 kB
[ Download ]

preview

World ADC Weltkongress Antibody Drug Conjugates (26.10.2014 – 29.10.2014, San Diego)
PDF, 834.64 kB
[ Download ]

preview

ASH 2013 American Society of Hematology (06.12.2013 - 10.12.2013, New Orleans)
PDF, 41.61 kB
[ Download ]

preview

ASH 2012 American Society of Hematology, 8. - 11. Dez. 2012, Atlanta (USA)
PDF, 387.58 kB
[ Download ]

preview

Tassone et al.: Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 1;104(12):3688-96
[ Link ]

preview

Ikeda et al.: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.Clin Cancer Res. 2009, Jun 15;15(12):4028-37
[ Link ]

Clinical trials

Title

Indication

Status

 
Indatuximab Ravtansine (Study 983) Multiple myeloma Study ongoing

BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma

Link clinicaltrials.gov
 
Indatuximab Ravtansine (Study 975) Multiple myeloma Study completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

 
Indatuximab Ravtansine (Study 969) Multiple myeloma Study completed

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

 
Indatuximab Ravtansine* (Study 989) Solid tumors Study ongoing

An open-label, twostage Phase I/IIa dose escalation study of BT062 in metastatic triple receptor-negative breast cancer and in metastatic transitional cell carcinoma of the urinary bladder

Link clinicaltrialsregister.eu